Current medical management of diabetic foot infections

References

• Bloomgarden Z. American Diabetes Association 60th Scientific Sessions 2000. The Diabetic Foot. Diabetes Care24, 946–951 (2001).
   PubMedGoogle Scholar
• Boyko EJ, Lipsky BA. Infection and diabetes mellitus. In: Diabetes in America (2nd Edition). Harris I (Ed.). NIH, Washington, DC, USA, 485–496 (1995).
   Google Scholar
• Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care29, 1288–1293 (2006).
   PubMed Web of Science ®Google Scholar
• Pecoraro RE. Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes40, 1305–1313 (1991).
   PubMed Web of Science ®Google Scholar
• Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation: basis for prevention. Diabetes Care13, 513–521 (1990).
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care27, 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care26, 510–513 (2003).
   PubMed Web of Science ®Google Scholar
• Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired leucocyte functions in diabetic patients. Diabet. Med.14, 29–34 (1997).
   PubMed Web of Science ®Google Scholar
• Alexiewicz JM, Kumar D, SmogorzewskiM, Klin M, Massry SG. Polymorphonuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function. Ann. Intern. Med.123, 919–924 (1995).
   PubMedGoogle Scholar
• The Foot. Helal B, Wilson D. (Eds). Churchill Livingstone, London, UK, 710–738 (1988).
   Google Scholar
• Disorders of the Foot. Helfet A, Grudel D (Eds). JB Lippincot Co., PA, USA, 205–215 (1980).
   Google Scholar
• Disorders of the Foot and Ankle. Medical and Surgical Management. Volume 1 (2nd Edition). Jhass MH (Ed.). WB Saunders, London, UK, 484–519 (1991).
   Google Scholar
• Armstrong DG, Liswood PJ, Todd WF. Prevalence of mixed infections in the diabetic pedal wound. A retrospective review of 112 infections. J. Am. Podiatr. Med. Assoc.85, 533–537 (1995).
   PubMed Web of Science ®Google Scholar
• Bowling FL, Jude EB, Boulton AJ. MRSA and diabetic foot wounds: contaminating or infecting organisms? Curr. Diab. Rep.9, 440–444 (2009).
   PubMed Web of Science ®Google Scholar
• Citron DM, Goldstein EJ, Merriam CV et al. Bacteriology of moderate to severe diabetic foot infections and in vitro activity of antimicrobial agents. J. Clin. Microbiol.45, 2819–2828 (2007).
   PubMed Web of Science ®Google Scholar
• Gadepalli R, Dhawan B, Sreenivas V. A clinic–microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care8, 1727–1732 (2006).
   Google Scholar
• Reyzelman AM, Lipsky BA, Hadi SA, Harkless LB, Armstrong DG. The increased prevalence of severe necrotizing infections caused by non-group A streptococci. J. Am. Podiatr. Med. Assoc.89, 454–457 (1999).
   PubMedGoogle Scholar
• Brook I. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes. J. Med. Microbiol.27, 191–198 (1988).
   PubMedGoogle Scholar
• Kelly MJ. Wound infection: a controlled clinical and experimental demonstration of synergy between aerobic (Escherichia coli) and anaerobic (Bacteroides fragilis) bacteria. Ann. R. Coll. Surg. Engl.62, 52–59 (1980).
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet366, 1695–1703 (2005).
   PubMed Web of Science ®Google Scholar
• Raja NS. Microbiology of diabetic foot infections in a teaching hospital in Malaysia: a retrospective study of 194 cases. J. Microbiol. Immunol. Infect.40, 39–44 (2007).
   PubMedGoogle Scholar
• Lipsky BA, Berendt AR, Deery HG et al. Infectious Diseases Society of America. Diagnosis and treatment of diabetic foot infections.Clin. Infect. Dis.39, 885–910 (2004).
   PubMed Web of Science ®Google Scholar
• Bessman AN, Geiger PJ, Canawati H. Prevalence of Corynebacteria in diabetic foot infections. Diabetes Care15, 1531–1533 (1992).
   PubMedGoogle Scholar
• Hartemann-Heurtier A, Senneville E. Diabetic foot osteomyelitis. Diabetes Metab.34, 87–95 (2008).
   PubMed Web of Science ®Google Scholar
• Galkowska H, Podbielska A, Olszewski WL et al. Epidemiology and prevalence of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis in patients with diabetic foot ulcers: focus on the differences between species isolated from individuals with ischemic vs. neuropathic foot ulcers. Diabetes Res. Clin. Pract.84, 187–193 (2009).
   PubMed Web of Science ®Google Scholar
• Lipsky B. Medical treatment of diabetic foot infections. Clin. Infect. Dis.39, S104–S114 (2004).
   PubMed Web of Science ®Google Scholar
• Dang CN, Prasad YD, Boulton AJ, Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet. Med.20, 159–161 (2003).
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Tabak YP, Johannes RS, Vo L, Hyde L, Weigelt JA. Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia53(5), 914–923 (2010).
   PubMed Web of Science ®Google Scholar
• Tentolouris N, Petrikkos G, Vallianou N et al. Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin. Microbiol. Infect.12, 186–189 (2006).
   PubMed Web of Science ®Google Scholar
• Yates C, May K, Hale T et al. Wound chronicity, inpatient care, and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers. Diabetes Care32, 1907–1909 (2009).
   PubMed Web of Science ®Google Scholar
• Stanaway S, Johnson D, Moulik P, Gill G. Methicillin-resistant Staphylococcus aureus (MRSA) isolation from diabetic foot ulcers correlates with nasal MRSA carriage. Diabetes Res. Clin. Pract.75, 47–50 (2007).
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. Diabetes Res. Clin. Pract.80, 344–351 (2008).
   PubMed Web of Science ®Google Scholar
• Graves SF, Kobayashi SD, Deleo FR. Community-associated methicillin-resistant Staphylococcus aureus immune evasion and virulence. J. Mol. Med.88(2), 109–114 (2010).
   PubMedGoogle Scholar
• Hartemann-Heurtier A, Robert J, Jacqueminet S et al. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. Diabet. Med.21, 710–715 (2004).
   PubMed Web of Science ®Google Scholar
• Richard JL, Sotto A, Jourdan N et al. Risk factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers. Diabetes Metabolism34, 363–369 (2008).
   PubMedGoogle Scholar
• Varaiya AY, Dogra JD, Kulkarni MH, Bhalekar PN. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in diabetic foot infections. Indian J. Pathol. Microbiol.51, 370–372 (2008).
   PubMed Web of Science ®Google Scholar
• Pellizzer G, Strazzabosco M, Presi S et al. Deep tissue biopsy vs. superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection. Diabet. Med.18, 822–827 (2001).
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch. Intern. Med.150, 790–797 (1990).
   PubMedGoogle Scholar
• Sapico FL, Witte JL, Canawati HN, Montgomerie JZ, Bessman AN. The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features. Rev. Infect. Dis.6, S171–S176 (1984).
   PubMedGoogle Scholar
• Sharp GS, Bessman AN, Wagner FW Jr, Garland D, Reece E. Microbiology of superficial and deep tissues in infected diabetic gangrene. Surg. Gynecol. Obstet.149, 217–219 (1979).
   PubMedGoogle Scholar
• Sapico FL, Canawati HN, Witte JL, Montogomerie JZ, Wagner FW Jr, Bessman AN. Quantitative aerobic and anaerobic bacteriology of infected diabetic feet. Clin. Microbiol.12, 413–420 (1980).
   Google Scholar
• Chakraborti C, Le C, Yanofsky A. Sensitivity of superficial cultures in lower extremity wounds. J. Hosp. Med.5, 415–420 (2010).
   PubMed Web of Science ®Google Scholar
• Lipsky BA, International consensus group on diagnosing and treating the infected diabetic foot. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab. Res. Rev.20(Suppl. 1), S68–S77 (2004).
   PubMed Web of Science ®Google Scholar
• Gardner SE, Frantz RA. Wound bioburden and infection-related complication in diabetic foot ulcers. Biol. Res. Nurs.10, 44–53 (2008).
   PubMed Web of Science ®Google Scholar
• Teh J, Berendt T, Lipsky BA. Rational Imaging. Investigating suspected bone infection in the diabetic foot. BMJ339, b4690 (2009).
   Google Scholar
• Bernard L, Uçkay I, Vuagnat A et al. Two consecutive deep sinus tract cultures predict the pathogen of osteomyelitis. Int. J. Infect. Dis.14, e390–e393 (2010).
   PubMed Web of Science ®Google Scholar
• Agarwal S, Zahid M, Sherwani MK, Abbas M, Huda N, Kahn AO. Comparison of the results of sinus track culture and sequestrum culture in chronic osteomyelitis. Acta Orthop. Belg.71, 209–212 (2005).
   PubMedGoogle Scholar
• Ulug M, Avaz C, Celen MK, Gevik MF, Hosoglu S, Necmioglu S. Are sinus track cultures reliable for identifying the cuasative agent in chronic osteomyelitis? Arch. Orthop. Trauma Surg.129, 1565–1570 (2009).
   PubMedGoogle Scholar
• Berendt AR, Peters EJ, Bakker K et al. Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab. Res. Rev.24, S145–S161 (2008).
   PubMed Web of Science ®Google Scholar
• Butalia S, Palda VA, Sargeant RJ, Detsky AS, Mourad O. Does this patient with diabetes have osteomyelitis of the lower extremity? JAMA299, 806–813 (2008).
   PubMed Web of Science ®Google Scholar
• Dinh MT, Abad CL, Safdar N. Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: meta-analysis. Clin. Infect. Dis.47, 519–527 (2008).
   PubMed Web of Science ®Google Scholar
• Senneville E, Lombart A, Beltrand E et al. Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study. Diabetes Care31, 637–642 (2008).
   PubMed Web of Science ®Google Scholar
• Norden CW. Lessons learned from animal models of osteomyelitis. Rev. Infect. Dis.10, 103–110 (1988).
   PubMedGoogle Scholar
• Mader JT. Animal models of osteomyelitis. Am. J. Med.78, 213–217 (1985).
   PubMed Web of Science ®Google Scholar
• Jeffcoate WJ, Lipsky BA. Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. Clin. Infect. Dis.39, S115–S122 (2004).
   PubMed Web of Science ®Google Scholar
• Raad I, Hanna H, Jiang Y et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob. Agents Chemother.51, 1656–1660 (2007).
   PubMed Web of Science ®Google Scholar
• Yamaoka T. The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole–trimethoprim against intracellular phagocytized MRSA. J. Infect. Chemother.13, 141–146 (2007).
   PubMedGoogle Scholar
• Embil JM, Rose G, Trepman E et al. Oral antimicrobial therapy for diabetic foot osteomyelitis. Foot Ankle Int.27, 771–779 (2006).
   PubMed Web of Science ®Google Scholar
• Game FL, Jeffcoate WJ. Primarily non-surgical management of osteomyelitis of the foot in diabetes. Diabetologia51, 962–967 (2008).
   PubMed Web of Science ®Google Scholar
• Cunha BA. Oral and IV to PO switch antibiotic therapy of hospitalized patients with serious infections. Scand. J. Infect. Dis.40(11–12), 1004–1006 (2008).
   PubMed Web of Science ®Google Scholar
• Waagsbø B, Sundøy A, Paulsen EQ. Reduction of unnecessary IV. antibiotic days using general criteria for antibiotic switch. Scand. J. Infect. Dis.40, 468–473 (2008).
   PubMed Web of Science ®Google Scholar
• Daver NG, Shelburne SA, Atmar RL et al. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J. Infect.54, 539–544 (2007).
   PubMed Web of Science ®Google Scholar
• Gomis M, Barberán J, Sánchez B, Khorrami S, Borja J, García-Barbal J. Oral ofloxacin versus parenteral imipenem–cilastatin in the treatment of osteomyelitis. Rev. Esp. Quimioter12, 244–249 (1999).
   PubMedGoogle Scholar
• Yilmaz G, Aydin K, Iskender S, Caylan R, Koksal I. Detection and prevalence of inducible clindamycin resistance in staphylococci. J. Med. Microbiol.56, 342–345 (2007).
   PubMed Web of Science ®Google Scholar
• Invanz (ertapenem for injection) prescribing information. Merck and Co., Inc. Whitehouse Station. NJ, USA (March 2010).
   Google Scholar
• Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell KL, Gesser RM. General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin–tazobactam. Clin. Infect. Dis.35, S119–S125 (2002).
   Google Scholar
• Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis.42, S35–S39 (2006).
   PubMed Web of Science ®Google Scholar
• Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin. Infect. Dis.45, S191–S195 (2007).
   PubMed Web of Science ®Google Scholar
• Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med.166, 2138–2144 (2006).
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Lomaestro BM, Rotscahfer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis.49, 325–327 (2009).
   PubMed Web of Science ®Google Scholar
• Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am. J. Med.123, 182.e1–e7 (2010).
   PubMed Web of Science ®Google Scholar
• Jefferson KK, Goldmann DA, Pier GB. Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus biofilms. Antimicrob. Agents Chemother.49, 2467–2473 (2005).
   PubMed Web of Science ®Google Scholar
• Rose WE, Poppens PT. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphyloccoccus aureus. J. Antimicrob. Chemother.63, 485–488 (2008).
   PubMedGoogle Scholar
• Dunne WM Jr. Effects of subinhibitory concentrations of vancomycin or cefamandole on biofilm production by coagulase-negative staphylococci. Antimicrob. Agents Chemother.34, 390–393 (1990).
   PubMedGoogle Scholar
• Skhirtladze K, Hutschala D, Fleck T et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob. Agents Chemother.50, 1372–1375 (2006).
   PubMed Web of Science ®Google Scholar
• Raad I, Hanna H, Jiang Y et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob. Agents Chemother.51, 1656–1660 (2007).
   PubMed Web of Science ®Google Scholar
• Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin. Microbiol. Rev.23, 14–34 (2010).
   PubMed Web of Science ®Google Scholar
• Yamaoka T. The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole–trimethoprim against intracellular phagocytized MRSA. J. Infect. Chemother.13, 141–146 (2007).
   PubMedGoogle Scholar
• Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis.49, 1072–1079 (2009).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J. Infect. Dis.195, 202–211 (2007).
   PubMed Web of Science ®Google Scholar
• Singh SR, Bacon AE 3rd, Young DC, Couch KA. In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother.53, 4495–4497 (2009).
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Caillon J, Le Mabecque V et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J. Antimicrob. Chemother.51, 857–864 (2003).
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet358, 207–208 (2001).
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin–clavulanate. Clin. Infect. Dis.38, 17–24 (2004).
   PubMed Web of Science ®Google Scholar
• Itani KM, Weigelt J, Li JZ, Dattagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents26, 442–448 (2005).
   PubMed Web of Science ®Google Scholar
• Senneville E, Legout L, Valette M et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case–control study. J. Antimicrob. Chemother.54, 798–802 (2004).
   PubMed Web of Science ®Google Scholar
• Gerson SL, Kaplan SL, Bruss JB et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother.46, 2723–2726 (2002).
   PubMed Web of Science ®Google Scholar
• Wu VC, Wang YT, Wang CY et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin. Infect. Dis.42(1), 66–72 (2006).
   PubMed Web of Science ®Google Scholar
• Zyvox (linezolid) prescribing information. Pharmacia and Upjohn Company. Div. of Pfizer Inc. New York, NY, USA (December 2009).
   Google Scholar
• Niwa T, Suzuki A, Sakakibara S et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin. Ther.31, 2126–2133 (2009).
   PubMed Web of Science ®Google Scholar
• Tsuji Y, Hiraki Y, Matsumoto K et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J. Infect. Chemother. DOI: 10.1007/s10156-010-0080-6 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy27, 1189–1197 (2007).
   PubMed Web of Science ®Google Scholar
• Beekmann SE, Gilbert DN, Polgreen PM; IDSA Emerging Infections Network. Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn. Microbiol. Infect. Dis.62, 407–410 (2008).
   PubMed Web of Science ®Google Scholar
• Bosso JA. The antimicrobial armamentarium: evaluating current and future treatment options. Pharmacotherapy25, 55S–62S (2005).
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J. Antimicrob. Chemother.55, 240–245 (2005).
   PubMed Web of Science ®Google Scholar
• Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other β-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother.48, 2871–2875 (2004).
   PubMed Web of Science ®Google Scholar
• Traunmüller F, Schintler M, Metzler J et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J. Antimicrob. Chemother. DOI: 10.1093/jac/dkq109 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Cubicin (daptomycin) prescribing information. Cubist Pharmaceuticals Inc., Lexington, MA, USA (August 2010).
   Google Scholar
• Testa RT, Petersen PJ, Jacobus NV et al. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob. Agents Chemother.37, 2270–2277 (1993).
   PubMed Web of Science ®Google Scholar
• Garrison MW, Neumiller JJ, Setter SM. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant Gram-positive organisms. Clin. Ther.27, 12–22 (2005).
   PubMed Web of Science ®Google Scholar
• Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis.41, S333–S340 (2005).
   PubMed Web of Science ®Google Scholar
• Sotto A, Bouziges N, Jourdan N, Richard JL, Lavigne JP. In vitro activity of tigecycline against strains isolated from diabetic foot ulcers. Pathol. Biol. (Paris)55, 398–406 (2007).
   PubMedGoogle Scholar
• Tygacyl (tigecycline) prescribing information. Wyeth Pharmaceuticals Inc., Philadelphia, PA, USA (May 2010).
   Google Scholar
• Passarell J, Ludwig E, Liolios K et al. Exposure-response analyses of tigecycline tolerability in healthy subjects. Diagn. Microbiol. Infect. Dis.65, 123–129 (2009).
   PubMedGoogle Scholar
• Lipsky BA, Giordano P, Choudhri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin–tazobactam/amoxicillin–clavulanate. J. Antimicrob. Chemother.60, 370–376 (2007).
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Graham DR, Wilson SE et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin. Infect. Dis.46, 1683–1693 (2008).
   PubMed Web of Science ®Google Scholar
• Nannini EC, Stryjewski ME, Corey GR. Ceftaroline for complicated skin and skin-structure infections. Expert Opin. Pharmacother.11, 1197–1206 (2010).
   PubMed Web of Science ®Google Scholar
• Steed M, Rybak J. Ceftaroline: a new cephalosporin with activity against resistant Gram-positive pathogens. Pharmacotherapy30, 375–389 (2010).
   PubMed Web of Science ®Google Scholar
• Corey GR, Wilcox M, Talbot GH et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin. Infect. Dis.51, 641–650 (2010).
   PubMed Web of Science ®Google Scholar
• Jauregui LE, Babazadeh S, Seltzer E et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis.41, 1407–1415 (2005).
   PubMed Web of Science ®Google Scholar
• Busse K, Oltrogge K, Oxencis C, Peppard W. Dalbavancin: a review of its use in the treatment of Gram-positive infections. Clin. Med. Insights Ther.2, 7–13 (2010).
   Google Scholar
• Lauderdale TL, Shiau YR, Lai JF, Chen HC, King CH. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob. Agents Chemother.54, 1338–1342 (2010).
   PubMed Web of Science ®Google Scholar
• Lipsky B, Berendt A, Deery H et al. Infectious Disease Society of America. Guidelines for the diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis.39, 885–910 (2004).
   PubMed Web of Science ®Google Scholar